REDAVIA Deploys First Solar Farm in Kenya at Menengai Farmers Ltd
29.7.2020 11:00:00 EEST | Business Wire | Press release
REDAVIA, a global market leader of cost-effective, reliable, and clean solar power for businesses, deployed its first solar farm in Kenya for Menengai Farmers Ltd tea farm in Tigoni.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200729005045/en/
REDAVIA Solar Farm at Menengai Tea Farm (Photo: Business Wire)
For the first 20 years of its operations, Menengai Farmers Ltd successfully grew tea without any large electrical demands. However, in the mid-80’s, weather patterns in Tigoni changed requiring the installation of an irrigation system. As the tea farm and irrigation system have grown, so have Menengai Farmer Ltd’s energy needs, putting a strain on their operational budget.
Menengai Farmers Ltd turned to REDAVIA for a cost-efficient solution. REDAVIA provides solar energy under a flexible lease contract, enabling Menengai Farmers Ltd to reduce costs and increase their operational flexibility.
Designed for maximum ease, REDAVIA’s contract also includes installation, maintenance, and 24/7 technical monitoring. REDAVIA’s onsite engineers deployed the solar ground mount unit at the Menengai Farmers Ltd site. After a smooth deployment and early operation period, both parties are already planning to scale up the solar farm with a second phase of energy storage, allowing for independence from the national grid.
“We are happy to have found a company to manage the electrical costs of our irrigation system,” said Gideon Katiku, Farm Manager of Menengai Farmers Ltd. “The savings we make with REDAVIA will allow us to continue to grow our farm.”
Erwin Spolders, CEO & founder of REDAVIA, confirms, “Solar power reduces costs, generating savings that can be reinvested into the business, while also reducing the carbon footprint of the business. It’s a win-win scenario.”
About Menengai Farmers Ltd
Menengai Farmers Ltd was incorporated on 21st May 1964 and lies on 320 acres of land. The company specializes in the mass farming of tea leaves, which are then delivered to Maramba Tea Factory (a subsidiary of Menengai Farmers Ltd) for processing and packaging and sold to both local and export markets.
About REDAVIA
REDAVIA offers solar power for businesses in West and East Africa. The REDAVIA system is based on a pre-configured model, including high-performance solar modules and electrical components. It is easy to ship, set up, scale, and redeploy. Businesses benefit from a cost-effective, reliable, clean energy solution with minimal upfront investment or technical skills. Find out more at www.redaviasolar.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005045/en/
Contact information
Press Contact:
REDAVIA
Ann Karimi
+49 89 2426 8869
+254 (0) 703 458761
a.karimi@redaviasolar.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 16:00:00 EEST | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care tea
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 16:00:00 EEST | Press release
Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become operational infrastructure without corresponding security maturity. The report also reveals that AI environments are rapidly becoming more interconnected and business critical. Among organizations adopting AI, 64% now run vector databases, 55
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 16:00:00 EEST | Press release
As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity. The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom